- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: MILR1444A | RG3637 | TNX-650
Compound class: Antibody
Comment: Lebrikizumab is a clinical candidate anti-IL-13 monoclonal antibody.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
|No information available.|
|Summary of Clinical Use|
|This antibody was originally tested as a treatment for refractory Hodgkin's lymphoma but was later repurposed as a potential asthma treatment . The antibody entered Phase 2 trial for idiopathic pulmonary fibrosis (IPF) and Phase 3 trial for asthma. Business reports online indicate that Roche have discontinued lebrikizumab development in IPF following mixed results from their trials . Click here to view ClinicalTrails.gov's listing of current lebrikizumab trials.|
|Mechanism Of Action and Pharmacodynamic Effects|
|IL-13 induces airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion in allergic lung diseases such as asthma . These changes contribute to airway obstruction. Lebrikizumab was designed to neutralise circulating IL-13, thereby reducing disease symptoms .|